Gerhardt Attard, MD, PhD, on Prostate Cancer: Results From an After-Market Study on Enzalutamide
2017 ASCO Annual MeetingGerhardt Attard, MD, PhD, of The Royal Marsden Hospital and The Institute of Cancer Research, discusses trial results on continued enzalutamide post prostate-specific antigen progression in men with chemotherapy-naive metastatic castration-resistant prostate cancer. (Abstract 5004)
Related Videos
Taofeek K. Owonikoko, MD, PhD, on SCLC: Results of the ECOG-ACRIN 2511 Trial
Taofeek K. Owonikoko, MD, PhD, of Emory University, discusses study findings on cisplatin and etoposide in combination with veliparib or placebo for extensive stage small cell lung...
Jame Abraham, MD, on Breast Cancer: Expert Perspective on the MONARCH 2 Trial
Jame Abraham, MD, of the Cleveland Clinic, gives his views on findings on abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progress...
Julie Vose, MD, MBA, on DLBCL and FL: Expert Commentary on Two Studies
Julie Vose, MD, MBA, of the University of Nebraska Medical Center, discusses two hematologic abstracts: results from the OPTIMAL>60 study on radiotherapy to bulky disease PET-ne...
Toni K. Choueiri, MD, and Sumanta K. Pal, MD, on Top Kidney Cancer Abstracts: Expert Perspectives
Sumanta K. Pal, MD, of City of Hope, and Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, exchange views on the key papers in renal cell carcinoma presen...
Gary Rodin, MD, on Advanced Cancer: The CALM Psychological Intervention
Gary Rodin, MD, of the University of Toronto, discusses study findings on a systematic approach to alleviating distress and managing predictable challenges. (Abstract LBA10001)
